Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q53TN4

UPID:
CYBR1_HUMAN

ALTERNATIVE NAMES:
Cytochrome b reductase 1; Duodenal cytochrome b; Ferric-chelate reductase 3

ALTERNATIVE UPACC:
Q53TN4; B2RE79; B4DWD7; Q6KC16; Q6KC17; Q6P147; Q6ZR51; Q9H0Q8; Q9H5G5

BACKGROUND:
CYBRD1, known for its roles as Cytochrome b reductase 1, Duodenal cytochrome b, and Ferric-chelate reductase 3, is integral to iron homeostasis. It uses cytoplasmic ascorbate to reduce Fe(3+) to Fe(2+), aiding in iron uptake at the intestinal level. Its ability to regenerate extracellular ascorbate and act as a ferrireductase in various tissues, including airway epithelial cells, underscores its multifunctional nature. CYBRD1's potential as a cupric transmembrane reductase further highlights its versatility in metal ion metabolism.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of CYBRD1 offers promising avenues for developing treatments for conditions associated with iron absorption anomalies and oxidative damage, underscoring the therapeutic potential of targeting this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.